Affordable Access

Publisher Website

Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: Method validation and overcoming specific and non-specific binding at low concentrations

Journal of Chromatography B
Publication Date
DOI: 10.1016/j.jchromb.2012.01.033
  • Antidiabetic Agent
  • Onglyza™
  • Saxagliptin
  • Bms-477118
  • 5-Hydroxy Saxagliptin Metabolite
  • Dipeptide-Peptidase
  • Dpp4
  • Lc–Ms/Ms
  • Liquid Chromatography–Tandem Mass Spectrometry
  • Diastereomer
  • Protein Precipitation
  • Human Plasma
  • Cross-Validation
  • Pharmacology


Abstract A liquid chromatography and tandem mass spectrometry (LC–MS/MS) method was developed and validated to simultaneously determine the concentrations of saxagliptin (Onglyza™, BMS-477118) and its major active metabolite, 5-hydroxy saxagliptin to support pharmacokinetic analyses in clinical studies. The dynamic range of the assay was 0.1–50ng/mL for saxagliptin and 0.2–100ng/mL for 5-hydroxy saxagliptin. Protein precipitation (PPT) with acetonitrile was used to extract the analytes from plasma matrix before injecting on an Atlantis® dC18 column (50mm×2.1mm, 5μm) for LC–MS/MS analysis. The sample pre-treatment process was carefully controlled to disrupt DPP4-specific binding and non-specific binding observed at lower concentrations. The recoveries for both analytes were >90%. The assay was selective, rugged and reproducible; storage stability of at least 401 days at −20°C was demonstrated. Under these chromatographic conditions, the isomers of saxagliptin and 5-hydroxy saxagliptin were chromatographically separated from saxagliptin and 5-hydroxy saxagliptin. The assay has been used to support multiple clinical studies and regulatory approvals.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times